key: cord-0715148-ph0zn8ur
authors: Menestrina, Luca; Cabrelle, Chiara; Recanatini, Maurizio
title: COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19
date: 2021-03-09
journal: bioRxiv
DOI: 10.1101/2021.03.05.433897
sha: 2f99d54175cad8c3cbead573c801958f6be04bab
doc_id: 715148
cord_uid: ph0zn8ur

The COVID-19 pandemic poses a huge problem of public health that requires the implementation of all available means to contrast it, and drugs are one of them. In this context, we observed an unmet need of depicting the continuously evolving scenario of the ongoing drug clinical trials through an easy-to-use, freely accessible online tool. Starting from this consideration, we developed COVIDrugNet (http://compmedchem.unibo.it/covidrugnet), a web application that allows users to capture a holistic view and keep up to date on how the clinical drug research is responding to the SARS-CoV-2 infection. Here, we describe the web app and show through some examples how one can explore the whole landscape of medicines in clinical trial for the treatment of COVID-19 and try to probe the consistency of the current approaches with the available biological and pharmacological evidence. We conclude that careful analyses of the COVID-19 drug-target system based on COVIDrugNet can help to understand the biological implications of the proposed drug options, and eventually improve the search for more effective therapies.

The outbreak of the COVID-19 pandemic caused by SARS-CoV-2 at the beginning of 2020 has shocked the population worldwide. One year later, (February 2021) about 110 million confirmed cases of COVID-19 have been reported by WHO included more than 2.4 million deaths (https://covid19.who.int/). As expected, in such a mankind threatening situation, the scientific community put in place a great effort to help countering the spread of the virus, as evidenced among the other things by the huge number of papers dealing with various aspects of the disease appeared in the literature. For instance, the LitCovid literature hub 1 has collected more than 100,000 articles (February 18, 2021 access) covering arguments categorized as overview, disease mechanism, transmission dynamics, treatment, case report and epidemic forecasting.

As regards the COVID-19 treatment, the race to the vaccine against SARS-CoV-2 started immediately after the isolation of the viral genome 2 and gave the first results as soon as December 2020. Moreover, despite the exploration of different approaches like, e.g., the infusion of plasma from human survivors 3 , the pharmacological option, namely small molecule drugs and antibodies, is being actively pursued. However, the route to a new drug is long and costly, and the classical drug discovery pipeline is not compatible with the needs of rapid intervention on a population of millions of patients. At the moment, a viable alternative seems to be the repurposing of known drugs 4 , i.e., the use for the treatment of COVID-19 of drugs currently on the market for different therapeutic purposes.

Known drugs that are currently in clinical or pre-clinical study for the treatment of COVID-19 are aimed either at inhibiting viral or human targets involved in some of the processes of viral entry and replication, or at treating inflammation and tissue injury consequent to the viral infection 5, 6 . Even though it might seem that a direct antiviral approach could lead to a straightforward solution, only few of the existing antivirals have performed well in the clinic so far. On the other hand, a number of drugs used for the most disparate therapeutic indications and entered into clinical trials even with an uncertain rationale 7 are showing preliminary promising results. However, as it has been observed 8 , a real "repurposing tsunami" has invested the biomedical community, so much so that today it is difficult not only to keep track of the results of the trials, but also to follow the new proposals.

With the aim of helping researchers navigate the sea of outcomes and reports coming from the studies on COVID-19, some institutions and companies have developed online platforms that collect and organize both literature and data, eventually providing free access to the latter. For example, the already mentioned LitCovid hub 1 (https://www.ncbi.nlm.nih.gov/research/coronavirus/) is a daily updated source of relevant articles retrieved from PubMed. Other platforms dealing with data on drugs and chemicals, like, e.g., CHEMBL 9 (https://www.ebi.ac.uk/chembl/), PubChem 10 (https://pubchem.ncbi.nlm.nih.gov/), or DrugBank 11 (https://www.drugbank.ca/), have introduced special sections dedicated to COVID-19-related information. In addition, more specialized resources have appeared on the web to help accessing and analyzing COVID-19 data, mainly in the fields of epidemiology, genomics, interactomics, and, to a lesser extent, pharmacology. In this class of web tools, it is worth mentioning CORDITE (CORona Drug InTEractions database) 12 , a web interface that provides a database of potential drugs, targets, interactions, and relative publications obtained from a manually curated selection of literature sources. With the same purpose of facilitating the data analysis, the COVID-19 Drug and Gene Set Library was built as an online collection of COVID-19 related drugs and genes 13 . A comprehensive critical review on this kind of web tools has recently been published by Mercatelli et al. 14 .

Considering the great amount of valuable scientific information that has already been produced and published, and that will be presumably produced for some time more on COVID-19 related topics, it could be useful to look at the whole scenario of results, to foster the acquisition of that knowledge that can only emerge from consideration of both the totality and the complexity of data. In other words, and limiting ourselves to the pharmacological treatment issue, one might think of presenting and analyzing the information on proposed drugs in a way that takes into account not only the different types of data (chemical, biological, genomic, etc.), but also the relationships among them, that is on a network basis. The context is that of network medicine 15 . An attempt in this direction has recently been proposed by Korn et al. 16 , who developed a knowledgebase and an online platform (COVID-KOP) to integrate the existing biomedical information with the newly acquired knowledge on COVID-19. By means of this web tool, one can easily produce an aggregate graph connecting, e.g., COVID-19 phenotypic features to a drug studied for treating the disease, through the genes known to be linked to both. Still in the context of network medicine, CoVex is another platform that offers the user the possibility to explore the SARS-CoV-2 virus-host-drug interactome for drug repurposing aims 17 . In addition, we want to mention CovMulNet19 18 that at present looks like the most thorough network-based tool allowing to integrate the available genotypic and phenotypic information on COVID-19, like, SARS-CoV-2 proteins, their human partners, as well as symptoms, diseases, and drugs. Finally, Coronavirus canSAR 19 is a freely available resource that offers druggable interactomes of SARS-Cov-2 proteins and human proteins, as well as reports about 3D structures, drugs, and clinical trials.

In a specifically drug-focused context, the network medicine approach assumes the overcoming of the old "one drug, one target, one disease" concept in favor of a more outright "multi-drug, multitarget, multi-disease" approach 20 . The exploration of a such complex system of interactions can be aided by the construction of a drug-target network 21 . In reference to the COVID-19 case, drugtarget networks have been previously built and examined [22] [23] [24] especially with the aim of repurposing already approved drugs.

Here, we present the COVID-19 Drugs Networker (COVIDrugNet:

http://compmedchem.unibo.it/covidrugnet), a web application that offers a different point of view on anti-COVID-19 drugs by allowing a network-based analysis of the DrugBank dataset of potential repurposed drugs currently in clinical trial. The freely accessible application automatically retrieves the data from DrugBank, builds the drug-target network, and allows the user to carry out some basic network analysis. Moreover, we show how, using COVIDrugNet, some peculiar aspects of the proposed pharmacological options against COVID-19, in terms of substances, targets, and their interrelationships can be revealed. Although what is reported here is an instant analysis based on current data, the continuous updating of COVIDrugNet will allow us to follow the future development of the drugs proposed for the treatment of the disease, thus providing an always updated view of the COVID-19 system pharmacology.

The COVID-19 Drug Networker (COVIDrugNet, Figure 1 ) is a web tool designed for the exploration of the landscape of the drugs currently in clinical trials to combat the SARS-CoV-2 infection. The web app is based on a network approach that supports both visualization and analysis of the complex scenario of repurposed drugs for the COVID-19 and related conditions. The core of the web tool are the interactive networks and the additional features that allow one to explore drug and target data, as well as network properties. The main network is a bipartite Drug-Target network (DT, Figure 2a ), in which the nodes are drugs and targets, and are connected if a relation between them is reported in DrugBank. Since bipartite networks are usually investigated by compressing their information into two monopartite networks called projections 25 , COVIDrugNet provides two of such networks only having drugs or targets as nodes: in the following, we refer to them as Drug and Target projections, (DP and TP, respectively; Figures 2b and 2c).

As regards the user interface, it is basically divided into the main and the Advanced Tools blocks.

The first one allows users to immediately access the main body of information, capturing the holistic view of the current drug repurposing status for COVID-19. However, a more in-depth examination of the data is possible, by taking advantage of some more specialized graph analysis tools provided in Advanced Tools.

In detail, the main block includes the graph, and the Charts and Plots and Graph Properties sections ( Figure 1 ). As mentioned before, the heart of each web page is the interactive graph with its related information box (Node Info) that provides a summary documentation of single drug/target nodes hovered over or individually selected. The box contains links to some databases providing the available information related to individual properties of both drugs and targets. In addition, a multiple node selection brings up the Inspected Data hidden section that displays detailed information of the selected nodes in a tabular format. By the way, networks and tables can be downloaded in different formats to allow an external analysis of the data.

Node coloring options are provided, useful to visualize some node attributes related to therapeutic, biological, or network-based features. For instance, the user can decide to color the nodes according to the Anatomical Therapeutic Chemical (ATC) code in the DP, or protein family, protein class or cellular location in the TP. Moreover, in the drug-target network and in both projections, it is possible to color the nodes based on some network attributes -i.e., degree, centrality measures or node grouping -considering the entire graph or the major component. To examine all these properties at a glance, the web tool also provides the Chart and Plot section, in which the pie charts -or bar chart in the case of the ATC code coloring option -are updated accordingly to the node coloring option to show the relative proportions between the values of that property. In this area of the projection web pages, the web tool also provides the plot of the nodes' degree distribution.

Among the graph interactive features, the Highlight a node dropdown menu is useful to find nodes by name, and the button HIGHLIGHT BY PROPERTY allows a customized filtering on node properties to highlight and/or download a specific node selection. In the Graph Properties section, some centrality measures useful to analyze the network topology are displayed in a downloadable 

In Figure 2 , the graphs representing the networks generated by COVIDrugNet are displayed. The DT network is a disconnected network with a large connected component accounting for 83.2% of nodes (1212 out of 1457). This structure reminds that of the general drug-target network reported elsewhere 21 , where most drugs have more than one target and several drugs can share the same target(s). However, from inspection of the graph, it immediately appears that there are two drug nodes that heavily affect the network topology by showing an exceedingly high degree compared to all other nodes: Fostamatinib and Artenimol, having 305 and 186 direct neighbors, respectively. For both drugs, this reflects a number of reported targets that is considerably higher than the average (<7), being 6.9 and 4.2 times higher, respectively, than that of Cannabidiol that, with 44 targets, is the third in rank for the highest number of neighbors in the DT network. Indeed, these two drugs show a peculiar behavior strongly affecting the network structure not only in the DT, but consequently also in the TP graph where they cause the formation of two highly intra-connected clumps of nodes. To take this aspect under consideration and possibly clarify its role in respect to the topology of both the whole drug-target network and the projections, in the following, we compared the results of the network analyses carried out on the entire networks and on the graphs containing all nodes except Artenimol, Fostamatinib and their exclusive direct neighbors.

As a first step in the analysis, we tried to assess the character of the monopartite projection networks DP (278 nodes) and TP (1179 nodes), i.e., whether they belong to the random network category or are scale-free. Scale-free networks have a characteristic organization, in which there is a limited number of nodes with a high number of neighbors (called hubs) and an abundance of nodes having a low degree 29 . This arrangement can be found in plenty of real-world networks, from the World Wide Web to citations in science, from social interactions to metabolic maps 29, 30 .

Both DP and TP show a significant difference from an equivalent (same number of nodes and probability of edge creation) Erdős-Rényi graph 31 ( Figure S1 ). To further investigate on the scalefreeness of the networks, we considered three properties for each graph: the degree distribution, the relationship between clustering coefficient and degree, and the ability to withstand targeted attacks compared to random failures.

In order to address the scale-free character of both networks by evaluating the fitness of the degree distribution to a power-law, we employed the approach reported by Broido et al. 32 , which applied a previously defined rigorous method 33 . This analysis was carried out on both the entire DP and TP networks and also in cases where Artenimol and Fostamatinib as well as their exclusive direct neighbors were removed.

In the Drug Projections, the degree distribution could be described by a power-law, suggesting that these networks are plausibly scale-free ( Figure S2a,b) . However, other heavy-tailed distributions cannot be ruled out. The situation for the Target Projections is less clear-cut ( Figure S2c ,d), at least in the case of the entire network. To advance an explanation for these results, we observe that, these networks are small, such that they would probably not provide enough data for clearly electing a distribution form. Still, they are unequivocally dissimilar to random networks.

The inspection of both the clustering coefficient and the robustness evaluation is best illustrated considering the two projections one at a time.

Looking at the DP network and specifically at its clustering coefficient, it shows a tendency to decrease as the degree increases ( Figure S3a ,b), implicating the existence of a few hubs connecting peripheral nodes of high degree. Also, there is an evident distinction between the response to a targeted attack and to a random failure 34 ( Figure S4a ). In the first case, nodes with the highest degree are progressively removed from the network, causing it to break apart quickly. On the other hand, if the nodes to be dismissed are chosen randomly, the connectedness of the network is almost unaffected. Notably, these findings are strengthened by the fact that carrying out the same investigation on a network from which Artenimol and Fostamatinib are excluded, leads to almost identical results ( Figure S4b ).

The same examination carried out on the TP network does not yield equally unambiguous conclusions. As stated above, the targets linked to Artenimol and Fostamatinib compose two almost-clique aggregations, which distort the morphology of the network. The relationship between clustering coefficient and degree is strongly dependent on the presence of these two exceptionally connected drugs ( Figure S3c,d) . When they are not taken into account, the inverse proportionality is fairly visible. Nevertheless, if they are considered, the scatterplot displaying this relationship is warped, due to the formation of two separate but remarkably dense groups representing the targets connected to Artenimol and Fostamatinib. The check of the robustness of the network by comparing the responses to targeted attacks or random failures gives a result that agrees with that obtained from the DP network. The communities related to the two "super-spreaders" simply introduce a delay in the fragmentation of the network, since they are made of a multitude of nodes with equally high degree ( Figure S4c,d) . Anyhow, this shift does not alter the network robustness to random failures and the susceptibility to targeted attacks.

As a final remark on the networks organization, we stress that all results and conclusions presented here are just a snapshot of the continuously evolving COVID-19 drug repurposing scene, and that it will be worthwhile to follow the time progression of this system. For instance, in the future, the growth of the network could smooth out or even hide the effects of Artenimol and Fostamatinib that now we observe so evidently. In respect of this, we recognize a different response of the DP and TP networks to the influence of these nodes. The former is less affected, since the vast majority of the targets related to both drugs are not shared by others, such that the information related to these proteins vanishes in the projection process. On the contrary, the latter suffers a huge impact, showing a situation that is antithetical to the previous one. Here, the proteins amass together constituting two highly intra-connected jumbles, which are poorly linked to the rest of the network. A continuous growth and the ability of self-organizing are two key features of scale-free networks, which frequently describe real complex systems 29 . These characteristics are shown by both projections, and indeed their scale-freeness is supported by their degree distribution, the relation of clustering coefficient to degree, and their robustness. Mainly due to the influence of Artenimol and Fostamatinib, these properties are manifest in the DP network, but not so neat in the TP one.

To illustrate the capabilities of COVIDrugNet, in the following, we report some example considerations that can be derived from the analysis of the projection graphs of both drugs (DP) and targets (TP).

Examining the DP network with nodes colored by ATC code in the case of Fostamatinib, in the next section, we show that it is able to hit multiple targets involved in critical viral processes, a mechanism that might be at the basis of its favorable preclinical profile 40 .

The TP network of Figure 2c Another interesting aspect emerging from inspection of the interactome of Figure 4 is that 20 human proteins (blue circles with pink contour) bind to two viral targets, thus acting as bridges between two node communities and playing a key role in the formation of the large connected component of the graph (Table 4 ). From a drug discovery perspective, such proteins would be ideal targets to fight the virus, as neutralizing them would help to disrupt the network of interactions necessary to carry on the viral infection and replication processes. Unfortunately, none of these proteins appear in the TP network, implying that there is no substance targeting them among those listed in the DrugBank database of repurposed drugs presently in clinical trial. However, we browsed some databases (DrugBank 11 , DrugCentral 42 and ChEMBL 9 ) in the search for bioactive substances reported to bind these 20 proteins and found that 4 of them are reported as targets of known drugs ( Table 5 ). As can be seen from Table 5 , many of the drugs listed therein have not yet been considered for therapy, while some of them are already in clinical trial for COVID-19 treatment even though their action on the proteins in the interactome is not reported in DrugBank.

The former ones could be further possible candidates for COVID-19 drug repurposing in light of their ability to interfere with more than one process critical for the virus.

Our study is not exempt from some drawbacks that are common in data analysis, and regard mainly the data availability and quality. We based COVIDrugNet on the DrugBank Dashboard dedicated to COVID-19 pandemic, and although this public and free resource is known for the high reliability of the datasets, missing data or delayed updating can occur. This is evident for some drugs under clinical trial shown in Table 5 that have known targets yet not reported in their DrugBank file.

Moreover, not all the drugs or proteins investigated here are completely characterized and classified, and this adds some uncertainty and noise to our results. Also, some bias could be incorporated in the knowledge we started from. For instance, the number of targets associated to a specific drug could considerably depend on the amount of research carried out on that medicine rather than on the actual biological interactions it has. This issue could be partially mitigated by a more extensive integration of data from a wider variety of databases. Very similar considerations can be drawn on the other databases that we exploited to retrieve auxiliary data: STRING 43 , DisGeNet 44 , SWISS-MODEL 45 , RCSB-PDB 46 , UniProt 47 and ChEMBL 9 . Furthermore, as mentioned in the "Methods" section, the drug-target network was built considering only protein targets, hence nucleic acid targets were not included. However, biomolecular targets other than proteins are a minority 48 and this led us to not integrate them.

Despite the massive efforts of the scientific community, SARS-CoV-2 and COVID-19 continue to be largely puzzling. Experimental assays are the solid ground on which we all start to build our hypotheses, yet also these investigations may have bias and a moderate amount of uncertainty. We have to keep this into consideration, when examining the merged interactomes by Gordon et al. 23 and Chen et al. 41 given their considerable difference. Additionally, the identification of a proteinprotein interaction in vitro unfortunately does not guarantee that the same interaction occurs also in vivo.

The COVID-19 pandemic poses a huge problem of public health that requires the implementation of all available approaches to contrast it, and drugs are one of them. In this context, we observed an have been able to single out some human proteins that contact two viral counterparts, and that might be possible new targets for anti-COVID-19 drugs. Finally, given that, as already noticed by others 7 , several treatments proposed for COVID-19 are still lacking a known mechanism of viral inhibition or even a pharmacological rationale, careful analyses of the drug-target data as those reported in the present work might help to understand the molecular implications of these pharmacological options, and eventually improve the search for more effective therapies.

The set of drugs in clinical trial for the treatment of COVID-19 (659 at January 14 th 2021) was retrieved from the dedicated web page of DrugBank (https://www.drugbank.ca/covid-19). Both experimental unapproved substances, and drugs in clinical trials were considered, and duplicates were removed (more than one trial is going on for some drugs). The set was also filtered for both the number of heavy atoms (to exclude inorganic compounds), and the availability of data (a drug was not added if it was not present in the PubChem database). This cleaning step reduced the number of drugs considered to 375. From the same site and from PubChem, we gathered some features related to structure, as well as pharmacological classification, pharmacodynamics, and pharmacokinetics of each drug (Table 1) . Drugs for which no targets were reported in DrugBank were discarded (278 remaining). As regards the drug targets, they were retrieved from DrugBank, and in this case we collected some information on classification, biology, and pharmacology of each protein. A detailed description of the features and the data sources are reported in Table 2 .

We chose to inspect the data in the form of a graph. All networks presented in the web app and in the paper were built by means of the NetworkX software 49 .

Some suitable node attributes (Degree, Closeness Centrality, Betweenness Centrality, Eigenvector Centrality, Clustering Coefficient, VoteRank) were calculated through NetworkX. The only property we tweaked was the result of the VoteRank because its algorithm draws up a ranking of nodes based on an iterative voting system 50 without assigning a specific value to each one of them.

Thus, we translated this ranking into a score for each node on the basis of its position and the total number of nodes with the following method:

IF node in rank score = length(rank) -index_in_rank(node) ELSE score = 0

Dividing a network into groups, clusters, or communities could be useful to unveil not trivial patterns of interaction. It is accomplished by splitting the network into subgroups that have the fewest possible number of connections between them 51 . In this work, we took advantage of (and provide access to in the webtool) three of the most common algorithms for this purpose: spectral clustering 26 , Girvan-Newman community detection 27 , and greedy modularity community detection 28 .

The first one makes use of the spectrum of the graph Laplacian to convey the information about the graph partition 26 . The division is then carried out on this data by a k-means clustering algorithm (see the Supplementary Information for more detail) . In the second case, communities are recognized employing the Girvan-Newman method 27 . It is a hierarchical method based on the progressive removal of the edges with the highest betweenness centrality from the graph, causing it to break into sets of smaller constituents. The partition with the best modularity is shown, but the user can manually choose an arbitrary number of communities in the web tool. The greedy modularity community detection method 28 pursues the graph division through a bottom-up approach (opposite to the previous one), by exploiting a "greedy" algorithm that progressively associates the nodes into groups that maximize the modularity. It starts with all nodes separated into single communities and recursively merges the couple of them that brings to the highest modularity increasing, until the point that joining two communities would lead to a modularity reduction.

These tasks were accomplished through in-house Python scripts, mainly making use of the packages NetworkX and Scikit-learn 52 .

A network is commonly considered to be scale-free if the degree distribution of its nodes follows a power-law 29 , which has the form:

where the scaling exponent α is higher than 1 (usually between 2 and 3) and the degree value x is equal or greater than xmin (which is always higher than 1). To the best of our knowledge, the most severe scale-freeness test is presented by Broido et al. 32 that take advantage of a rigorous mathematical procedure 33 to assess the validity of a power-law distribution to describe the investigated degrees. Here, we followed their approach probing the fitting of a power-law to the degree distributions of both projected networks DP and TP (with and without the Artenimol and Fostamatinib nodes). As a first step, the parameters of the best fitting power-law are determined (xmin with a standard Kolmogorov-Smirnov minimization approach, and then α with a discrete maximum likelihood estimation) employing the Python package Powerlaw 53 . Then, the fitting is evaluated considering the p-value of the Kolmogorov-Smirnov distance (computed with a semiparametric bootstrap), and of the xmin and α (bootstrap). If p ≥ 0.1, the degree distribution is considered plausibly scale-free. Lastly, the chosen power-law distribution is compared to four nonscale-free alternatives (using loglikelihood ratio tests), to evaluate if it is favored over the others.

Such alternatives are the exponentially truncated power-law, the exponential, the stretched exponential (Weibull) and the lognormal. This entire procedure was carried out using an in-house Python script, with a large employment of the Python package Powerlaw. A more thorough explanation and method validation are provided in the Supplementary Information.

Scale-free networks (contrary to random Erdős-Rényi graphs) have an exceptional tolerance against random failures, but at the same time they are very vulnerable to targeted attacks 34 . We investigated the robustness of these networks evaluating their diameter (as a measure of interconnectivity) throughout a process of node removal. We took into account both targeted attacks and random failures and compared the results. In the first case, at every iteration the node with the highest degree was chosen and removed. In the other case, a node was selected randomly and eliminated. In this latter condition, the average of multiple 100 runs was considered in order to avoid misinterpretations induced by a single random choice. This procedure was carried out through an in-house Python script.

COVIDrugNet is mainly composed by the collector and the web tool itself. Both are written in Python, but the purpose of the former is to collect the data from web databases, build the graphs, compute some properties, and store everything in pickle format. The latter, instead, retrieves the data from the created database and sets up the front-end part of COVIDrugNet with Python Dash 54 .

with the web tool. M.R. was in charge of overall direction, planning, and supervision. All authors provided critical feedback and helped in the interpretation of data, tested and provided original contributions to the improvement of the app, and wrote the paper. All authors read and approved the final manuscript.

The full code for the collection, building and analysis of the networks is available in the GitHub repository at https://github.com/LucaMenestrina/COVIDrugNet. It is entirely written in Python and makes use of the packages listed in the Supporting Information. COVIDrugNet is a public web tool available at http://compmedchem.unibo.it/covidrugnet. All data generated or analyzed in this study is publicly available and is included in this article (and its supplementary information files) or on the GitHub repository (in which data will be updated every two weeks). Furthermore, some data is easily downloadable from the web tool itself: all tables in tab-separated values (tsv) format and the networks in various formats (adjacency list, pickle, cytoscape json, graphml, gexf, edges list, multiline adjacency list, tsv, png and jpg). The networks were generated by means of the Python package NetworkX 49 .

A bar chart displaying the count of nodes for every first level ATC code (anatomical/pharmacological main group). The total count is higher than the number of nodes in the DP because more than one ATC code can be assigned to a single drug.

The Virus-Host-Drug Interactome built on the basis of the merged datasets from Gordon et al. 23 and Chen et al. 41 . Proteins (circles) are displayed in red if viral and in blue if human. The human proteins present in the TP network are shown as yellow circles, and the corresponding drugs currently in clinical trials against COVID-19 as green squares. The human proteins binding more than one viral target are highlighted as blue circles with pink contour. The network visualization was generated through Cytoscape 3.8.2 56 . 

Keep up with the latest coronavirus research

Primed for global coronavirus pandemic: Emerging research and clinical outcome

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

Drug repurposing: progress, challenges and recommendations

Old drugs for a new virus : repurposed approaches for combating COVID-19

Drug repurposing approach to combating coronavirus: Potential drugs and drug targets

A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development. IUPHAR Review 29

COVID-19 and the drug repurposing tsunami

The ChEMBL database in 2017

PubChem in 2021: new data content and improved web interfaces

DrugBank 5.0: A major update to the DrugBank database for 2018

CORDITE: The curated CORona Drug InTERactions database for SARS-CoV-2. iScience

The COVID-19 drug and gene set library

Web tools to fight pandemics: the COVID-19 experience

COVID-KOP: integrating emerging COVID-19 data with the ROBOKOP database

Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing

CovMulNet19, integrating proteins, diseases, drugs, and symptoms: A network medicine approach to COVID-19

Coronavirus canSAR -A data-driven, AI-enabled, drug discovery resource for the research community

Network pharmacology: The next paradigm in drug discovery

Drug-target network

Network medicine framework for identifying drug repurposing opportunities for COVID-19

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Bipartite graphs in systems biology and medicine: A survey of methods and applications

A tutorial on spectral clustering

Community structure in social and biological networks

Fast algorithm for detecting community structure in networks

Emergence of scaling in random networks

Scale-Free Networks: Complex Webs in Nature and Technology

On random graphs I

Scale-free networks are rare

Power-law distributions in empirical data

Error and attack tolerance of complex networks

Pathophysiology of COVID-19: Mechanisms underlying disease severity and progression

Extrapulmonary manifestations of COVID-19

Bacterial and fungal superinfections in critically ill patients with COVID-19

Antibiotic use in patients with COVID-19: A 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey

COVID-19: a complex multisystem disorder

Repurposing Fostamatinib to combat SARS-CoV-2-induced acute lung injury

Comprehensive analysis of the host-virus interactome of SARS-CoV-2

DrugCentral 2021 supports drug discovery and repositioning

STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

The DisGeNET knowledge platform for disease genomics: 2019 update

The SWISS-MODEL Repository-new features and functionality

The Protein Data Bank

UniProt: A worldwide hub of protein knowledge

A comprehensive map of molecular drug targets

Exploring network structure, dynamics, and function using NetworkX

Identifying a set of influential spreaders in complex networks

An Introduction

Scikit-learn: Machine Learning in Python

Powerlaw: A Python package for analysis of heavytailed distributions

Plotly Technologies Inc. Collaborative data science

The Apache Software Foundation

Cytoscape: A software Environment for integrated models of biomolecular interaction networks

This work was supported by University of Bologna. The authors wish to thank Fabrizio De Ponti for the helpful discussions and Riccardo Ocello for the support in the server management. 

The web tool deployment was carried out with Apache 55 through the mod_wsgi interface in an Ubuntu server.